Trials
21 active
35 in total · 19 in the EU
Targets
—
None known yet
What this is
- How it works
- BTK inhibitor
- How it’s given
- “Remibrutinib film coated tablets in the respective dose strength of the parent study.”In the company’s words, NCT07456891 on ClinicalTrials.gov
- Tested for
- Chronic Spontaneous Urticaria (4 trials), Hidradenitis Suppurativa (4 trials), Relapsing Multiple Sclerosis (3 trials), Chronic Pruritus of Unknown Origin (2 trials), Chronic Inducible Urticaria, Chronic Spontaneous Urticaria (CSU), Generalized Myasthenia Gravis, IgE-Mediated Food Allergy and 7 more
- Main trialPhase 3
- “The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.”In the company’s words, NCT05513001 on ClinicalTrials.gov
- Other names
- LOU064 · Rhapsido
Other drugs for Chronic Spontaneous Urticaria
Coming up12
- 22 Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- 17 May 2027Phase 3 trial completes · ClinicalTrials.gov
- 3 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- 23 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- 29 Nov 2027Phase 1 trial completes · ClinicalTrials.gov
- 7 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 25 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- 24 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 26 Feb 2029Phase 3 trial completes · ClinicalTrials.gov
- 30 Mar 2029Phase 3 trial completes · ClinicalTrials.gov
- 25 Jul 2029Phase 3 trial completes · ClinicalTrials.gov
- 19 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 10 NovCompletion date moved: 2027-12-21 to 2027-11-29 · ClinicalTrials.gov NCT07855276
- 9 NovCompletion date moved: 2031-10-29 to 2031-10-15 · ClinicalTrials.gov NCT07665437
FDA approvals1
- 30 Sep 2025RHAPSIDO NOVARTIS · Application NDA218436
Trials35
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 26 Aug 2024 | An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib | |
| Phase 3Active, not recruiting | 17 Sep 2025 | Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. | |
| Phase 3Active, not recruiting | 11 May 2026 | A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines | |
| Phase 3Active, not recruiting | 21 Jul 2026 | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) | |
| Phase 3Active, not recruiting | 22 Jul 2026 | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) | |
| Phase 3Active, not recruiting | 3 Nov 2026 | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up | |
| Phase 3Active, not recruiting | 22 Feb 2027 | A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | |
| Phase 3Active, not recruiting | 17 May 2027 | A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | |
| Phase 3Active, not recruiting | 3 Jun 2027 | A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 3Active, not recruiting | 25 Feb 2028 | A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | |
| Phase 3Recruiting | 24 May 2028 | Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks | |
| Phase 3Recruiting | 26 Feb 2029 | A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) | |
| Phase 3Recruiting | 30 Mar 2029 | A 52-week Study of Remibrutinib in IgE-mediated Food Allergy | |
| Phase 3Recruiting | 25 Jul 2029 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | |
| Phase 3Recruiting | 19 Dec 2029 | A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) | |
| Phase 3Recruiting | 3 Dec 2030 | A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | |
| Phase 3Recruiting | 15 Oct 2031 | An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS | |
| Phase 3Recruiting | 30 Jan 2033 | Remibrutinib Open Label Roll-over Post-trial Access Protocol | |
| Phase 2Recruiting | 23 Aug 2027 | Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria | |
| Phase 2Recruiting | 7 Dec 2027 | A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR) | |
| Phase 1Recruiting | 29 Nov 2027 | A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS | |
| Phase 3Completed | 8 Dec 2023 | A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines | |
| Phase 3Completed | 18 Dec 2023 | A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines | |
| Phase 3Completed | 27 Dec 2023 | A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines | |
| Phase 3Completed | 25 Apr 2024 | A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks. | |
| Phase 2Terminated | 27 Apr 2020 | Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients | |
| Phase 2Completed | 14 Jan 2021 | This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines | |
| Phase 2Terminated | 23 Nov 2021 | A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome | |
| Phase 2Completed | 9 Sep 2022 | An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU | |
| Phase 2Completed | 4 Dec 2024 | Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 2Completed | 11 Mar 2025 | Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts | |
| Phase 1Completed | 27 Jan 2020 | Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064 | |
| Phase 1Completed | 14 Dec 2023 | A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants | |
| Phase 1Completed | 12 Oct 2025 | A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. | |
| Phase 1Ended | not given | A Phase 1, participant blinded, randomized, placebo-controlled study to investigate the remibrutinib exposure in CSF (cerebrospinal fluid) in healthy participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026